New Security Health Plan updates to commercial, exchange, and Medicare formularies

Security Health Plan may add rules about whether and how certain drugs are covered during the year. Your patients may not currently be using these products, but we want to provide you with these updates to alert you of any future changes. Due to regulatory timelines on different lines of business, the actual implementation date of the changes may vary.

Effective no sooner than January 1, 2024:

- Unbranded insulin aspart, insulin aspart mix 70/30, insulin lispro, and insulin lispro mix 75/25 “generic” products will be added to formulary as the preferred insulin products.
- Novolog® insulin and Novolog® 70/30 insulin will be non-preferred for all lines of business.
- Fiasp® insulin will be non-preferred for commercial and exchange lines of business.

Please consider prescribing your patients the unbranded insulin products to encourage use of effective, low-cost insulin.